The Alzheimer's Drug Discovery Foundation (ADDF) supported the first diagnostic test for Alzheimer's disease and helped fund approximately 20% of all treatments for Alzheimer's currently in clinical trials.
A full 100% of every dollar donated to us goes directly to fund research. To date, we have invested more than $80 million to fund over 500 drug research programs at academic centers and biotechnology companies in 18 countries.
In 2012, the US Food and Drug Administration (FDA) approved Amyvid™, the first diagnostic test for Alzheimer's disease. The ADDF seed-funded the research for Amyvid™ from 2000–2004. This successful technology shows how early financial support for high-risk projects can lead to the development of innovative drugs and diagnostics for Alzheimer's.
Amyvid™ is the first project we've funded to receive FDA approval, but many more are now in or advancing toward human clinical trials, the final stages of development.
After receiving ADDF support, our grantees have gone on to receive commitments of over $2 billion in follow-on funding from government, pharmaceutical companies and venture capital firms. This is a testament to our rigorous review progress and to the resources we provide grantees. Because a single drug can cost as much as $2 billion to develop, follow-on funding is important to ensure our grantees can advance their breakthrough drug research.
Today, we continue to provide early support for pioneering ideas, and we also invest a growing percentage of our funds in clinical trials for drugs further in development. We will conquer Alzheimer's disease.